Advertisement

Experimental Data on the Antimycobacterial Activity of Isoprodian(R)

  • Richard Urbanczik
Part of the Chemotherapy book series (CT, volume 3)

Abstract

Until today, it is not common to discuss the chemotherapy of “mycobacterioses” as a single topic. Treatment of tuberculosis, leprosy etc. is considered more or less separately, in spite of the obvious advantage of a common approach recognized e.g. by Mayer (1964) or possibly even earlier. Prothionamide (PTH) and/or diaphenylsulphone (DDS) were claimed to increase the antimycobacterial activity of rifampicin (RMP, Freerksen and Rosenfeld, 1972) or of isoniazid (INH, Freerksen, 1973). Also, it has been reported by Middlebrook and Yegian (1946) that no resistance to streptomycin (SM) occured in mycobacteria exposed in vitro simultaneously to SM and DDS. According to Shepard (1972), B-663 (LAMPRENE), ethionamide (ETH) and DDS were reported to give mutually additive results with their combinations against M.leprae; longer bacterial growth delay was observed in M.leprae by Matsuo (1974) with RMP+DDS than with RMP alone. The rationale for combined chemotherapy in tuberculosis has been for years that the development of mycobacterial resistance to each drug alone may be prevented.

Keywords

Single Topic Combine Chemotherapy Antimycobacterial Activity Bacteriostatic Effect Peroral Administration 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. Awaness, A.M. and Mitchison, D.A., (1973), Tubercle, 54, 153PubMedCrossRefGoogle Scholar
  2. Dost, F.H., (1968), Grundlagen der Pharmakokinetik, Georg Thieme, StuttgartGoogle Scholar
  3. Franz, H., Urbanczik, R., Stoll, K. and Müller, U., (1974), Praxis der Pneumologie, 28, 605Google Scholar
  4. Freerksen, E., and Rosenfeld, M., (1972), Arzneimittel-Forschung (Drug Research), 22, 1235Google Scholar
  5. Freerksen, E., (1973), Lecture presented during the 13th Meeting of the North German Association for Tuberculosis and Pulmonary Diseases, Celle ( Germany ), October 19–21Google Scholar
  6. Garrett, E.R., (1958), Antibiotics and Chemotherapy, 8, 8Google Scholar
  7. Hobby, G.L. and Lenert, T.F., (1972), American Review of Respiratory Diseases, 105, 292Google Scholar
  8. Jenne, J.W. and Beggs, W.H., (1973), American Review of Respiratory Diseases, 107, 1013Google Scholar
  9. Matsuo, Y., (1974), Japanese Journal of Microbiology, 18, 15PubMedGoogle Scholar
  10. Mayer, R.L., (1964), Advances in Tuberculosis Research ( S.Karger, Basel/New York ) 13, 219Google Scholar
  11. Middlebrook, G. and Yegian, D., (1946), American Review of Tuberculosis, 54, 553PubMedGoogle Scholar
  12. Radenbach, K.L., (1973), Internist, 14, 100PubMedGoogle Scholar
  13. Shepard, C.C., (1972), International Journal of Leprosy, 40, 33Google Scholar
  14. Urbanczik, R., (1974a), Arzneimittel-Forschung (Drug Research), 24, 723Google Scholar
  15. Urbanczik, R., (1974b), Infection, 2, 80PubMedCrossRefGoogle Scholar

Copyright information

© Plenum Press, New York 1976

Authors and Affiliations

  • Richard Urbanczik
    • 1
  1. 1.Schwarzwald-SanatoriumSaarstickstoff Fatol Ltd.SchoembergGermany

Personalised recommendations